Jazz Pharmaceuticals (NASDAQ:JAZZ) had its price objective hoisted by Barclays from $182.00 to $200.00 in a research note released on Monday morning, The Fly reports. Barclays currently has an overweight rating on the specialty pharmaceutical company’s stock.
Several other analysts have also recently commented on the company. HC Wainwright reissued a hold rating and issued a $147.00 price target on shares of Jazz Pharmaceuticals in a report on Monday, November 11th. Wells Fargo & Co reissued a buy rating on shares of Jazz Pharmaceuticals in a report on Wednesday, August 14th. Sanford C. Bernstein reissued a market perform rating and issued a $150.00 price target on shares of Jazz Pharmaceuticals in a report on Monday, October 14th. Zacks Investment Research cut Jazz Pharmaceuticals from a buy rating to a hold rating and set a $138.00 price target for the company. in a report on Friday, September 13th. Finally, Piper Jaffray Companies cut Jazz Pharmaceuticals from an overweight rating to a neutral rating and reduced their price target for the company from $205.00 to $142.00 in a report on Wednesday, August 21st. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and ten have issued a buy rating to the stock. Jazz Pharmaceuticals currently has an average rating of Buy and a consensus price target of $167.00.
JAZZ opened at $150.38 on Monday. The company has a debt-to-equity ratio of 0.56, a current ratio of 3.89 and a quick ratio of 3.71. The business has a 50 day simple moving average of $132.43 and a 200-day simple moving average of $132.84. The stock has a market capitalization of $8.55 billion, a P/E ratio of 12.29, a P/E/G ratio of 1.18 and a beta of 1.15. Jazz Pharmaceuticals has a 12 month low of $113.52 and a 12 month high of $154.44.
Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings results on Tuesday, November 5th. The specialty pharmaceutical company reported $4.10 EPS for the quarter, beating the consensus estimate of $3.19 by $0.91. The business had revenue of $537.70 million during the quarter, compared to analysts’ expectations of $523.92 million. Jazz Pharmaceuticals had a return on equity of 27.99% and a net margin of 29.61%. The company’s quarterly revenue was up 14.6% compared to the same quarter last year. During the same period last year, the firm earned $3.58 EPS. Research analysts anticipate that Jazz Pharmaceuticals will post 14.15 EPS for the current year.
In related news, CEO Bruce C. Cozadd sold 500 shares of the firm’s stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $130.00, for a total value of $65,000.00. Following the completion of the transaction, the chief executive officer now directly owns 311,855 shares of the company’s stock, valued at approximately $40,541,150. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 4.30% of the company’s stock.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Signaturefd LLC increased its stake in Jazz Pharmaceuticals by 56.3% in the 2nd quarter. Signaturefd LLC now owns 200 shares of the specialty pharmaceutical company’s stock valued at $29,000 after purchasing an additional 72 shares in the last quarter. Captrust Financial Advisors increased its stake in Jazz Pharmaceuticals by 120.0% in the 2nd quarter. Captrust Financial Advisors now owns 220 shares of the specialty pharmaceutical company’s stock valued at $31,000 after purchasing an additional 120 shares in the last quarter. MUFG Americas Holdings Corp purchased a new position in Jazz Pharmaceuticals in the 3rd quarter valued at approximately $29,000. Stonebridge Capital Advisors LLC purchased a new position in Jazz Pharmaceuticals in the 2nd quarter valued at approximately $37,000. Finally, AdvisorNet Financial Inc purchased a new position in Jazz Pharmaceuticals in the 3rd quarter valued at approximately $37,000. 89.10% of the stock is owned by hedge funds and other institutional investors.
Jazz Pharmaceuticals Company Profile
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.
Recommended Story: CD Ladder
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.